1-15 of 15
Linda Ho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Clinical Trials & Observations
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason M. Melear, Ian W. Flinn, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Matthew Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte A. Yimer, Miguel Islas-Ohlmayer, Ameet Patel, Leland Metheny, Asad Dean, Vishal Rana, Mitul D. Gandhi, John S Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood blood.2024024681.
https://doi.org/10.1182/blood.2024024681
Published: 2024
Includes: Supplemental data
Journal Articles

Durability of Complete Responses in Patients from the ECHELON-3 Study

Christopher Yasenchak, Nancy L. Bartlett, Jeong-A Kim, Uwe Hahn, Craig A. Portell, Francesco Zaja, Thorsten Zenz, Cecily Forsyth, Jin Seok Kim, Seok-Goo Cho, Jae-Yong Kwak, Hao-Yuan Wang, Herve Ghesquieres, Grzegorz S. Nowakowski, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Frank Stenner
Journal: Blood
Blood (2024) 144 (Supplement 1): 3101.
https://doi.org/10.1182/blood-2024-194158
Published: 2024
Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Uwe Hahn, Nancy L. Bartlett, Jeong-A Kim, Krimo Bouabdallah, Nicholas Forward, Tsai-Yun Chen, Vincent Camus, Ming-Chung Wang, Philippe Carassou, Enrico Derenzini, Hung Chang, Fritz Offner, Herve Ghesquieres, Grzegorz S. Nowakowski, Christopher Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Craig A. Portell
Journal: Blood
Blood (2024) 144 (Supplement 1): 4489.
https://doi.org/10.1182/blood-2024-200914
Published: 2024
Journal Articles

Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Nancy L. Bartlett, Jeong-A Kim, Uwe Hahn, Isabelle Fleury, Kamel Laribi, Juan Miguel Bergua Burgues, Craig A. Portell, Melina Boutin, Blanca Sanchez Gonzalez, Selay Lam, Sung Yong Oh, Judit Mészáros Joergensen, Young Rok Do, Herve Ghesquieres, Grzegorz S. Nowakowski, Christopher Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Keenan Fenton, Vincent Ribrag
Journal: Blood
Blood (2024) 144 (Supplement 1): 4483.
https://doi.org/10.1182/blood-2024-200836
Published: 2024
Journal Articles

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Eva Domingo Domenech, Brian Hess, Steven Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Harsh R. Shah, Wojciech Jurczak, Alessandro Re, Uwe Hahn, H. Miles Prince, Wenchuan Guo, Griffith Davis, Linda Ho, Christopher Yasenchak, Hun Ju Lee
Journal: Blood
Blood (2024) 144 (Supplement 1): 460.
https://doi.org/10.1182/blood-2024-200992
Published: 2024
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte A. Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Scott Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Chris Yasenchak
Journal: Blood
Blood (2023) 142 (Supplement 1): 608.
https://doi.org/10.1182/blood-2023-173972
Published: 2023
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett, John M. Burke, Ryan C Lynch, Eva Domingo Domenech, Brian Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Wojciech Jurczak, Alessandro Re, Uwe Hahn, H. Miles Prince, Wenchuan Guo, Linda Ho, Rose C. Beck, Christopher A. Yasenchak, Hun Ju Lee
Journal: Blood
Blood (2023) 142 (Supplement 1): 611.
https://doi.org/10.1182/blood-2023-172574
Published: 2023
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2022) 140 (Supplement 1): 763–765.
https://doi.org/10.1182/blood-2022-156553
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Hun Ju Lee, Jeremy S. Abramson, Nancy L. Bartlett, John M. Burke, Ryan C. Lynch, Domingo Domenech Eva, Brian T. Hess, Steven R. Schuster, Yuliya Linhares, Rod Ramchandren, Mitul Gandhi, Rex Mowat, Harsh Shah, Giuseppe Rossi, Uwe H Hahn, Henry Miles Prince, Linda Ho, Wenchuan Guo, Christopher A. Yasenchak, David J. Straus
Journal: Blood
Blood (2022) 140 (Supplement 1): 9399–9401.
https://doi.org/10.1182/blood-2022-156576
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Matthew R. Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Amanda L. Gillespie-Twardy, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2454.
https://doi.org/10.1182/blood-2021-147891
Published: 2021
Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress)

Ian W. Flinn, Judah Friedman, Linda Ho, Hun Ju Lee
Journal: Blood
Blood (2021) 138 (Supplement 1): 1369.
https://doi.org/10.1182/blood-2021-152231
Published: 2021
Journal Articles

Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

Clinical Trials & Observations
Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann S. LaCasce, Beth A. Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera
Journal: Blood
Blood (2021) 138 (6): 427–438.
https://doi.org/10.1182/blood.2020009178
Published: 2021
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2852.
https://doi.org/10.1182/blood-2019-122968
Published: 2019
Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2836.
https://doi.org/10.1182/blood-2019-122969
Published: 2019
Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 237.
https://doi.org/10.1182/blood-2019-124866
Published: 2019